{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:30:20Z","timestamp":1778657420716,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12325-019-00994-7","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T20:05:47Z","timestamp":1561061147000},"page":"1906-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)"],"prefix":"10.1007","volume":"36","author":[{"given":"Kevin V.","family":"Carlson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita V.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita M.","family":"Kristy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol R.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"2","key":"994_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167\u201378.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"994_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/nau.22609","volume":"33","author":"MJ Drake","year":"2014","unstructured":"Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622\u20134.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"994_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/nau.23477","volume":"37","author":"LC Powell","year":"2018","unstructured":"Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018;37(4):1241\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"994_CR4","first-page":"2278","volume":"11","author":"J Corcos","year":"2004","unstructured":"Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol. 2004;11(3):2278\u201384.","journal-title":"Can J Urol"},{"issue":"1","key":"994_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1464-410X.2007.07198.x","volume":"101","author":"S Herschorn","year":"2008","unstructured":"Herschorn S, Gajewski J, Schulz J, Corcos J. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int. 2008;101(1):52\u20138.","journal-title":"BJU Int"},{"issue":"11","key":"994_CR6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"1","key":"994_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","volume":"80","author":"I Milsom","year":"2012","unstructured":"Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90\u20136.","journal-title":"Urology"},{"issue":"5","key":"994_CR8","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015;193(5):1572\u201380.","journal-title":"J Urol"},{"issue":"2","key":"994_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/17512433.2017.1275570","volume":"10","author":"CR Chapple","year":"2017","unstructured":"Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017;10(2):131\u201351.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"994_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17\u201330.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"994_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543\u201362.","journal-title":"Eur Urol"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","volume":"69","author":"SM Vouri","year":"2017","unstructured":"Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2017;69:77\u201396.","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"994_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324\u201333.","journal-title":"Eur Urol"},{"issue":"2 Suppl","key":"994_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","volume":"68","author":"P Abrams","year":"2006","unstructured":"Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68(2 Suppl):17\u201328.","journal-title":"Urology"},{"issue":"5","key":"994_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2016.04.033","volume":"70","author":"CR Chapple","year":"2016","unstructured":"Chapple CR, Kelleher CJ, Evans CJ, et al. A narrative review of patient-reported outcomes in overactive bladder: what is the way of the future? Eur Urol. 2016;70(5):799\u2013805.","journal-title":"Eur Urol"},{"key":"994_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cct.2018.05.006","volume":"70","author":"ES Rovner","year":"2018","unstructured":"Rovner ES, Carlson KV, Deal AS, et al. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): rationale, design, and methodology. Contemp Clin Trials. 2018;70:83\u20137.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"994_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/nau.22559","volume":"34","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Thompson CL, Lai J-S, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255\u201363.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"994_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/nau.20455","volume":"27","author":"E Piault","year":"2008","unstructured":"Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire. Neurourol Urodyn. 2008;27(3):179\u201390.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"994_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/03007995.2017.1419170","volume":"34","author":"R Freeman","year":"2018","unstructured":"Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785\u201393.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"994_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/nau.22844","volume":"35","author":"V Khullar","year":"2016","unstructured":"Khullar V, Amarenco G, Angulo JC, et al. Patient-reported outcomes with the \u03b23-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2016;35(8):987\u201394.","journal-title":"Neurourol Urodyn"},{"key":"994_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12955-018-0892-0","volume":"16","author":"S Herschorn","year":"2018","unstructured":"Herschorn S, Staskin D, Tu LM, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16:69.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"994_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"P Abrams","year":"2017","unstructured":"Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827\u201338.","journal-title":"World J Urol"},{"issue":"1","key":"994_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/nau.23315","volume":"37","author":"D Robinson","year":"2018","unstructured":"Robinson D, Kelleher C, Staskin D, et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn. 2018;37(1):394\u2013406.","journal-title":"Neurourol Urodyn"},{"key":"994_CR24","unstructured":"Agency for Healthcare Research and Quality (US). Section\u00a012, adverse event detection, processing, and reporting. In: Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for evaluating patient outcomes: a user\u2019s guide [internet]. 3rd ed. Rockville (MD); 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK208615\/ . Accessed Apr 30, 2019."},{"key":"994_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","volume":"189","author":"S Yamada","year":"2018","unstructured":"Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130\u201348.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"994_CR26","doi-asserted-by":"publisher","first-page":"O152","DOI":"10.1111\/luts.12237","volume":"11","author":"D Kato","year":"2019","unstructured":"Kato D, Tabuchi H, Uno S. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: a Japanese post-marketing surveillance study. Low Urin Tract Symptoms. 2019;11(2):O152\u201361.","journal-title":"Low Urin Tract Symptoms"},{"issue":"2","key":"994_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/luts.12148","volume":"10","author":"Y Nozawa","year":"2018","unstructured":"Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study. Low Urin Tract Symptoms. 2018;10(2):122\u201330.","journal-title":"Low Urin Tract Symptoms"},{"issue":"10","key":"994_CR28","doi-asserted-by":"publisher","first-page":"e12996","DOI":"10.1111\/ijcp.12996","volume":"71","author":"AS Wagg","year":"2017","unstructured":"Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK general practice prescription database. Int J Clin Pract. 2017;71(10):e12996.","journal-title":"Int J Clin Pract"},{"issue":"6 Suppl 1","key":"994_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.urology.2004.10.047","volume":"64","author":"A Tubaro","year":"2004","unstructured":"Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2\u20136.","journal-title":"Urology"},{"key":"994_CR30","doi-asserted-by":"crossref","unstructured":"Buckley BS, Lapitan MCM, Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008. Prevalence of urinary incontinence in men, women, and children\u2014current evidence: findings of the Fourth International Consultation on Incontinence. Urology. 2010;76(2):265\u201370.","DOI":"10.1016\/j.urology.2009.11.078"},{"issue":"7","key":"994_CR31","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132\u20138.","journal-title":"BJU Int"},{"issue":"2","key":"994_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00345-009-0490-1","volume":"29","author":"Y-S Lee","year":"2011","unstructured":"Lee Y-S, Lee K-S, Jung JH, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol. 2011;29(2):185\u201390.","journal-title":"World J Urol"},{"issue":"2","key":"994_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.juro.2011.03.114","volume":"186","author":"AD Markland","year":"2011","unstructured":"Markland AD, Richter HE, Fwu C-W, Eggers P, Kusek JW. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011;186(2):589\u201393.","journal-title":"J Urol"},{"issue":"8","key":"994_CR34","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1185\/03007995.2014.918028","volume":"30","author":"M Jimenez-Cidre","year":"2014","unstructured":"Jimenez-Cidre M, Costa P, Ng-Mak D, et al. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. Curr Med Res Opin. 2014;30(8):1557\u201364.","journal-title":"Curr Med Res Opin"},{"key":"994_CR35","doi-asserted-by":"crossref","unstructured":"Irwin DE, Milsom I, Kopp Z, Abrams P, Epic Study Group. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029\u201337.","DOI":"10.1016\/j.eururo.2008.01.027"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00994-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T01:31:57Z","timestamp":1721439117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00994-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00994-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}